Stevens-Johnson Syndrome: Clinical Trials

5 trials for Stevens-Johnson Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated, 1 unknown. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 3, Terminated 1, Unknown 1
Phase 22Terminated 1, Unknown 1

Follow Stevens-Johnson Syndrome: new trials by email Literature Review of Stevens-Johnson Syndrome trials Research Report on Stevens-Johnson Syndrome

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NATIENS: Optimal Management and Mechanisms of SJS/TEN
Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4 - Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Phase 3CompletedVanderbilt University Medical Center22023-03-212025-12-17
Severe Bullous Drug Eruption and Filgrastim
Filgrastim, Placebo - Rare Diseases, Toxic Epidermal Necrolyses
Phase 2 / Phase 3UnknownHospices Civils de Lyon422022-05-132024-05-08
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Intravenous immunoglobulin - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Phase 3CompletedNihon Pharmaceutical Co., Ltd102012-10-012014-07-02
Lamictal in the Treatment of Post-Herpetic Neuralgia
Lamictal in the treatment of Post-Herpetic Neuralgia - Neuralgia, Postherpetic
Phase 2 / Phase 3TerminatedGeorge Washington University2005-02-012013-03-13
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
Cultivated conjunctival transplantation - Pterygium, Ocular Surface Disease
Phase 3CompletedSingapore National Eye Centre802001-10-012010-01-13

Narrower conditions

Drug-Related Side Effects and Adverse Reactions (1)  ·  Neuralgia, Postherpetic (1)  ·  Pterygium (1)  ·  Rare Diseases (1)

Broader conditions

Chemically-Induced Disorders (5)  ·  Dermatitis (5)  ·  Drug Eruptions (5)  ·  Drug Hypersensitivity (5)  ·  Erythema (5)  ·  Erythema Multiforme (5)  ·  Hypersensitivity (5)  ·  Hypersensitivity, Delayed (5)  ·  Immune System Diseases (5)  ·  Mouth Diseases (5)  ·  Skin Diseases (5)  ·  Skin Diseases, Vesiculobullous (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Stomatitis (5)  ·  Stomatognathic Diseases (5)

Interventions

Etanercept (1)  ·  Filgrastim (1)  ·  Immunoglobulins, Intravenous (1)  ·  Lamotrigine (1)

Sponsors

George Washington University (1)  ·  Hospices Civils de Lyon (1)  ·  Nihon Pharmaceutical Co., Ltd (1)  ·  Singapore National Eye Centre (1)  ·  Vanderbilt University Medical Center (1)

Countries

United States (2)  ·  France (1)  ·  Japan (1)  ·  Singapore (1)

Top investigators

Donald T Tan, FRCS (1)  ·  Elizabeth J Phillips, MD (1)  ·  Leonard P Ang, FRCS (1)  ·  Perry K. Richardson, M.D. (1)

Results publications

PMID 15161841, PMID 15287367